ALZ-101 **Phase 1b clinical study** in patients with Alzheimer's disease

Study: Double-blind, randomized, placebo-controlled study on safety, tolerability and immunogenicity.
Part A - ALZ-101 (125 and 250 µg) or placebo, given at weeks 0, 4, 8 and 16, if not eligible for Part B, follow-up for additional 48 weeks
Part A2 - ALZ-101 (400 µg), given at weeks 0, 4, 8 and 16, follow up 4 weeks
Part B - ALZ-101 (250 µg), given at week 0, 4, 8 and 16 and for additional 48 weeks

Patient population: Patients between 50-80 years, MCI due to AD or mild AD*, CSF pattern consistent with amyloid plaque load and indicative of AD pathology.

Endpoints:
Primary; Safety, tolerability - **Secondary:** Immunogenicity (Aβ-specific) - **Exploratory:** Biomarkers (CSF & blood) and cognition



*according to National Institute of Aging – Alzheimer's Association (NIA-AA)
MCI – Mild Cognitive Impairment; AD – Alzheimer's Disease; CSF – Cerebrospinal fluid; Aβ – amyloid-beta